Cosmo NVCMOPF -3.22%82 Days Payable is 62.53 as of Dec. 2025, which is 65% below its 10-year median of 176.26. GuruFocus rates CMOPF with a GF Score™ of 82/100 and a GF Value™ of $53.54 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 920 Drug Manufacturers companies, Cosmo NV ranks worse than 65.11% on this metric.
Cosmo NV's average Accounts Payable for the
six
months ended in Dec. 2025 was $11.3 Mil. Cosmo NV's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $32.8 Mil.
Hence, Cosmo NV's Days Payable for the
six
months ended in Dec. 2025 was 62.53.
The historical rank and industry rank for Cosmo NV's Days Payable or its related term are showing as below:
CMOPF'
s Days Payable Range Over the Past 10 Years
Min: 59.43 Med: 176.26 Max: 426.8
Current: 64.61
During the past 13 years, Cosmo NV's highest Days Payable was 426.80. The lowest was 59.43. And the median was 176.26.
CMOPF's Days Payable is ranked worse than 65.11% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs CMOPF: 64.61
Cosmo NV's Days Payable
declined
from Dec. 2024 (99.37) to Dec. 2025 (62.53).
It may suggest that Cosmo NVaccelerated paying its suppliers.
Cosmo NV Days Payable Related Terms
Cosmo NV Days Payable Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Cosmo NV's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Days Payable distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cosmo NV's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV (CMOPF) has a Days Payable of 62.53 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cosmo NV and its competitors. This is 65% below median its historical median of 176.26. Over the past decade, Cosmo NV's Days Payable has ranged from 59.43 to 426.80. According to the industry distribution chart, Cosmo NV ranks #599 out of 920 companies in the Drug Manufacturers industry, placing it in the top 65.1%.
Is Cosmo NV's Days Payable too high?
Cosmo NV's current Days Payable of 62.53 is 65% below median its 10-year median of 176.26. Over the past 10 years, this metric has ranged from a low of 59.43 to a high of 426.80. The Drug Manufacturers industry median Days Payable is 90.84. Cosmo NV's value of 62.53 is 31.2% below this industry median. Based on the distribution chart, Cosmo NV ranks #599 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cosmo NV has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #599 out of 920 companies for Days Payable. This places Cosmo NV in the lower half of its industry. The industry median Days Payable is 90.84. Cosmo NV's value of 62.53 is 31.2% below this benchmark. Historically, Cosmo NV's own Days Payable has ranged from 59.43 to 426.80 over the past decade. While the company's 10-year median is 176.26 vs. the industry median of 90.84, Cosmo NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current Days Payable of 62.53 is 31.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Days Payable is 62.53, which is 65% below median its own 10-year median of 176.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $53.54, compared to a current price of $82.00 — trading 53.2% above its estimated fair value. The current Days Payable is 62.53, which is 65% below median its 10-year median of 176.26 and 31.2% below the Drug Manufacturers industry median of 90.84. Cosmo NV's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Days Payable is 62.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $82.00 is trading 53.2% above its estimated GF Value™ of $53.54.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
Days Payable: 62.53 (65% below median its 10-year median of 176.26)
GF Value™: $53.54 vs. price of $82.00 (53.2% above fair value)
Industry Position: 31.2% below the Drug Manufacturers median (#599 of 920)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
82GF Score
Get the complete analysis for CMOPF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
